Cimzia vs Stelara for Crohn's Disease: How They Compare

Cimzia and Stelara are two subcutaneous biologics for moderate-to-severe Crohn's disease that work through fundamentally different mechanisms. Cimzia (certolizumab pegol) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the cimzia vs stelara crohn's decision.

Anti-TNF vs IL-12/23 Mechanism

Cimzia binds TNF-alpha and reduces inflammation throughout the body and in the gut. Stelara binds the p40 subunit shared by IL-12 and IL-23, blocking both cytokines. IL-23 is a central driver of Th17-mediated inflammation in Crohn's, while IL-12 contributes to Th1 inflammation. The certolizumab vs ustekinumab distinction shapes both speed of onset and the long-term safety profile. Cimzia's broader TNF blockade produces faster systemic anti-inflammatory effects. Stelara's IL-12/23 inhibition produces strong efficacy with a cleaner infection profile.

Efficacy in Crohn's

Cimzia's Crohn's efficacy rests on PRECISE-1 and PRECISE-2, which showed significant clinical response and remission benefits over placebo. Stelara's Crohn's efficacy rests on UNITI-1 (biologic-experienced), UNITI-2 (biologic-naive), and IM-UNITI (maintenance). Across these trials, Stelara showed meaningful efficacy in both biologic-naive and biologic-experienced populations, with particularly strong maintenance data. No head-to-head trial has directly compared Cimzia with Stelara in Crohn's. Indirect comparisons suggest Stelara produces comparable clinical remission rates to Cimzia in biologic-naive patients and stronger response in anti-TNF experienced patients.

Onset of Action

Cimzia produces meaningful Crohn's response by week 6 based on PRECISE. Stelara's onset is slightly slower, with meaningful response often evident by week 6 to 8 after IV induction. For Crohn's patients with active symptoms who need rapid control, Cimzia's slightly faster onset can be useful. For patients weighing long-term safety and administration, Stelara's response trajectory is generally acceptable.

Safety Profiles

Cimzia carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Stelara's long-term safety data from more than a decade of post-marketing experience in psoriasis, Crohn's, and UC shows low rates of serious infection. For cimzia vs stelara side effects, Stelara's IL-12/23 mechanism is often associated with fewer systemic infections than anti-TNFs. Both drugs require TB and hepatitis B screening before starting.

IL-12/23 vs Anti-TNF Crohn's

For patients who have failed or lost response to an anti-TNF like Cimzia, a mechanism switch to Stelara's IL-12/23 pathway is supported by UNITI-1 data. Cycling within the anti-TNF class (for example, from Cimzia to Humira) typically delivers lower response rates than changing mechanism classes. For first-line Crohn's patients weighing these two options, both are reasonable starting points, with Cimzia favored for patients who prefer fully SC administration throughout and Stelara favored for those prioritizing long-term safety.

Administration and Dosing

Cimzia for Crohn's uses 400 mg SC at weeks 0, 2, and 4 for induction, then 400 mg every 4 weeks for maintenance, per UCB's prescribing information. Cimzia is all-SC throughout. Stelara starts with weight-based IV induction at week 0 (dose 260-520 mg based on weight), followed by subcutaneous maintenance of 90 mg every 8 weeks, per Janssen's Stelara prescribing information. For Crohn's patients comparing administration, Cimzia is fully SC, while Stelara requires one IV infusion before transitioning to SC maintenance. Stelara's every-8-week maintenance cadence is less frequent than Cimzia's every-4-week schedule.

Pregnancy Considerations

Cimzia's lack of an Fc region minimizes active placental transfer during pregnancy, resulting in very low infant drug levels at birth. Stelara undergoes active placental transfer via FcRn like other IgG biologics. For Crohn's patients who are pregnant or planning pregnancy and need to maintain biologic therapy through delivery, Cimzia's pregnancy profile is often preferred over Stelara.

Biosimilar Availability

Stelara's patent expired in 2023, and ustekinumab biosimilars launched in the US market beginning in 2025, which may lower acquisition costs for Stelara going forward. Cimzia has no biosimilar. For Crohn's patients where insurance favors a lower-cost ustekinumab biosimilar, Stelara (or its biosimilar) may be the most accessible option.

Choosing With Your GI

For a Crohn's patient deciding between Cimzia and Stelara, Cimzia tends to win on faster onset, fully SC administration throughout, pregnancy considerations, and fistulizing disease outcomes. Stelara tends to win on long-term safety, less frequent SC maintenance (every 8 weeks vs every 4 weeks), performance in anti-TNF experienced patients, and biosimilar cost savings. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.